Timothy D. Owens

2.8k total citations · 1 hit paper
27 papers, 1.8k citations indexed

About

Timothy D. Owens is a scholar working on Molecular Biology, Genetics and Organic Chemistry. According to data from OpenAlex, Timothy D. Owens has authored 27 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Genetics and 9 papers in Organic Chemistry. Recurrent topics in Timothy D. Owens's work include Chronic Lymphocytic Leukemia Research (11 papers), Chemical Synthesis and Analysis (9 papers) and Peptidase Inhibition and Analysis (6 papers). Timothy D. Owens is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Chemical Synthesis and Analysis (9 papers) and Peptidase Inhibition and Analysis (6 papers). Timothy D. Owens collaborates with scholars based in United States, Switzerland and Australia. Timothy D. Owens's co-authors include Jonathan A. Ellman, Tony P. Tang, J. Edward Semple, Allen G. Oliver, Frederick J. Hollander, Odile E. Levy, Andrew J. Souers, David Goldstein, J. Michael Bradshaw and Yan Lou and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Accounts of Chemical Research.

In The Last Decade

Timothy D. Owens

27 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

N-tert-Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines

2002 728 citations Jonathan A. Ellman, Timothy D. Owens et al. Accounts of Chemical Research profile →

Peers

Timothy D. Owens

GENET

ONCOL

Hiroshi Kosugi Japan

Kevin W. Kuntz United States

Matthew W. D. Perry Sweden

Semiramis Ayral‐Kaloustian United States

Alfred P. Spada United States

Bertrand J. Jean‐Claude Canada

Hon‐Wah Man United States

M. V. Ramana Reddy United States

Siavosh Mahboobi Germany

Diane H. Boschelli United States

Hiroshi Kosugi Japan

Timothy D. Owens

799 ×0.7

743 ×1.1

89 ×0.3

284 ×1.1

GENET

429 ×2.4

ONCOL

Citations per year, relative to Timothy D. Owens Timothy D. Owens (= 1×) peers Hiroshi Kosugi

Countries citing papers authored by Timothy D. Owens

Since Specialization

Citations

This map shows the geographic impact of Timothy D. Owens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy D. Owens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy D. Owens more than expected).

Fields of papers citing papers by Timothy D. Owens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy D. Owens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy D. Owens. The network helps show where Timothy D. Owens may publish in the future.

Co-authorship network of co-authors of Timothy D. Owens

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy D. Owens. A scholar is included among the top collaborators of Timothy D. Owens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy D. Owens. Timothy D. Owens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Owens, Timothy D., Patrick F. Smith, Andrew Redfern, et al.. (2021). Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clinical and Translational Science. 15(2). 442–450. 36 indexed citations

Langrish, Claire L., J. Michael Bradshaw, Michelle Francesco, et al.. (2021). Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. The Journal of Immunology. 206(7). 1454–1468. 68 indexed citations

Langrish, Claire L., et al.. (2020). 569 Rilzabrutinib (PRN1008) shows BTK-mediated mechanisms of action supporting clinical development for immune-mediated diseases. Journal of Investigative Dermatology. 140(7). S78–S78. 1 indexed citations

Basler, Michael, Michelle Lindström, Jacob LaStant, et al.. (2018). Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Reports. 19(12). 62 indexed citations

Venetsanakos, Eleni, Ken A. Brameld, Vernon T. Phan, et al.. (2017). The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance. Molecular Cancer Therapeutics. 16(12). 2668–2676. 22 indexed citations

Langrish, Claire L., J. Michael Bradshaw, Timothy D. Owens, et al.. (2017). PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura. Blood. 130. 1052–1052. 15 indexed citations

Brameld, Ken A., Timothy D. Owens, Erik Verner, et al.. (2017). Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. 60(15). 6516–6527. 84 indexed citations

Zhong, Yiming, Shuai Dong, Ethan Strattan, et al.. (2015). Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. Journal of Biological Chemistry. 290(10). 5960–5978. 37 indexed citations

Hill, Ronald J., J. Michael Bradshaw, Angelina Bisconte, et al.. (2015). THU0068 Preclinical Characterization of PRN1008, a Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a RAT Model of Collagen-Induced Arthritis. Annals of the Rheumatic Diseases. 74. 216–217. 9 indexed citations

10.

Lou, Yan, Zachary K. Sweeney, A. Kuglstatter, et al.. (2014). Finding the perfect spot for fluorine: Improving potency up to 40-fold during a rational fluorine scan of a Bruton’s Tyrosine Kinase (BTK) inhibitor scaffold. Bioorganic & Medicinal Chemistry Letters. 25(2). 367–371. 29 indexed citations

11.

Xu, Daigen, Yong Kim, Jennifer Postelnek, et al.. (2012). RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents. Journal of Pharmacology and Experimental Therapeutics. 341(1). 90–103. 105 indexed citations

12.

Ellman, Jonathan A., Timothy D. Owens, & Tony P. Tang. (2002). N-tert-Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines. Accounts of Chemical Research. 35(11). 984–995. 728 indexed citations breakdown →

13.

Owens, Timothy D., Andrew J. Souers, & Jonathan A. Ellman. (2002). The Preparation and Utility of Bis(sulfinyl)imidoamidine Ligands for the Copper-Catalyzed Diels−Alder Reaction. The Journal of Organic Chemistry. 68(1). 3–10. 74 indexed citations

14.

Souers, Andrew J., Timothy D. Owens, Allen G. Oliver, Frederick J. Hollander, & Jonathan A. Ellman. (2001). Synthesis and Crystal Structure of a Unique and Homochiral N,S-Bonded N,N‘-Bis(tert-butanesulfinyl)amidinate Rhodium(I) Complex. Inorganic Chemistry. 40(20). 5299–5301. 17 indexed citations

15.

Owens, Timothy D., Frederick J. Hollander, Allen G. Oliver, & Jonathan A. Ellman. (2001). Synthesis, Utility, and Structure of Novel Bis(sulfinyl)imidoamidine Ligands for Asymmetric Lewis Acid Catalysis. Journal of the American Chemical Society. 123(7). 1539–1540. 102 indexed citations

16.

Semple, J. Edward, et al.. (2000). Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic p1-ketoamide moieties. Bioorganic & Medicinal Chemistry Letters. 10(20). 2305–2309. 15 indexed citations

17.

Semple, J. Edward, et al.. (2000). New Synthetic Technology for Efficient Construction of α-Hydroxy-β-amino Amides via the Passerini Reaction¹. Organic Letters. 2(18). 2769–2772. 101 indexed citations

18.

Owens, Timothy D. & J. Edward Semple. (1998). Alkoxide-catalyzed ring-opening of a novel homosaccharin derivative: synthesis of potent, selective P3-lactam thrombin inhibitors containing P4-o-alkoxycarbonylbenzylsulfonamide residues. Bioorganic & Medicinal Chemistry Letters. 8(24). 3683–3688. 9 indexed citations

19.

Semple, J. Edward, et al.. (1998). Potent and selective thrombin inhibitors featuring hydrophobic, basic P3P4-aminoalkyllactam moieties. Bioorganic & Medicinal Chemistry Letters. 8(24). 3525–3530. 9 indexed citations

20.

Semple, J. Edward, David Rowley, Terence K. Brunck, et al.. (1997). ChemInform Abstract: Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1‐Argininal Derivatives Incorporating P3‐P4 Lactam Sulfonamide Moieties.. ChemInform. 28(8). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact